NE Vaccine

"Clostridium perfringens type A toxoid" and “NE vaccine” are the “working titles” for the world’s first vaccine for managing necrotic enteritis in broilers.

Developed by scientists at Intervet/Schering-Plough Animal Health, a world leader in poultry vaccines and enteric disease management, the maternal antibody vaccine is currently being used in U.S. broiler operations under a conditional license from the U.S. Department of Agriculture, which regulates biological products.

USDA agreed to issue a conditional license after Intervet/Schering-Plough Animal Health demonstrated a “reasonable expectation of efficacy” for the product. The vaccine, which fills a special need in the poultry industry, has already met all other USDA criteria for bird, human and environmental safety.

Intervet/Schering-Plough Animal Health is now conducting large-scale efficacy trials with the vaccine with major U.S. poultry companies while pursuing a full USDA license. Work is also being done to license the vaccine in Asia, Europe, Latin America and other major poultry markets.

The vaccine eventually will be marketed under the trademarked brand name, Netvax^®. Until this license has been obtained in the United States, however, we are required to use the product’s official generic name — Clostridium perfringens type A toxoid — or the shorter “NE vaccine” when presenting news and information about its efficacy and performance.

_{Netvax is property of Intervet International B.V. or affiliated companies or licensors and is protected by copyrights, trademark and other intellectual property laws.}